Skip to main content
. 2023 May 27;23:481. doi: 10.1186/s12885-023-10931-1

Table 2.

Short-term efficacy

EG( N= 119),n(%) CG(N = 98),n(%) p -value
CR 97 (81.5%) 69 (70.4%) 0.055
PR 12 (10.6%) 18 (18.4%) 0.079
SD 10 (8.4%) 11 (11.2%) 0.484
PD 0(0%) 0(0%)
ORR 109 (91.6%) 88 (90.8%) 0.484

EG The experimental group, CG The control group, ORR Overall response rate, CR + PR, CR Complete response, PR Partial response, SD stable disease, PD progressive disease